I made a personal TA on NYSE:PFE using FIB retracements to define when to buy the current pullback reversal. PFE is currently in a very clear uptrend an its previous pullbacks "reversed" at aroung 50%-61.8% FIB so i think that this current pullback is going to reverse at around 50%. Before buying: Check Rsi bounceoff and SMA positionning to form a...
Analyst Vernon Bernardino from H.C. Wainwright reiterated a buy rating and $19 price target on ARDS: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain." Aridis Pharmaceuticals Inc 's monoclonal...
Adagio Therapeutics announced its lead monoclonal antibody has neutralization activity against the Omicron variant of SARS-CoV-2. Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for prevention and treatment of COVID-19. Adagio is engaging with the FDA regarding protocol updates to its global Phase 2/3 clinical trials. My price target is...
The chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon! Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class...
first of all thanks for stopping by.. This text below will be posted on every timeframe Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar . On the big picture I'm looking at the 2 monthly chart To remove some noise and...
first of all thanks for stopping by.. This text below will be posted on every timeframe Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar . On the big picture I'm looking at the 2 monthly chart To remove some noise and...
first of all thanks for stopping by.. This text below will be posted on every timeframe Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar . On the big picture I'm looking at the 2 monthly chart To remove some noise and...
There is so much baked into the markets with vaccines. I expect PFE to have some downside to 55.66 to 55.47 as a T1 downside Target.
Arcturus Therapeutics Holdings Inc. $ARCT is set to be EBITDA positive in 2022 with a massive change in its revenue from 24.05M in 2021 to 326.44M in 2022. This is 12.57x increase in revenue. These numbers are estimates, but even with a large error margin we should see a drastic change in the price. Moreover, the decline from ATH was 80% and the price has been in...
New Data suggest COVAXIN (BBV152) may provide protection against current and future variants! data from a Phase 3 trial that included nearly 25,800 participants: 77.8% overall efficacy, 93.4% efficacy against severe illness and 65.2% efficacy against the Delta variant. 52 Week Range 0.28 - 18.77 My price target is the 10.30usd resistance.
With the small rise of pox news going on in the U.S., be it the second case of monkeypox this year , to smallpox vials found at a vaccine research facility in Pennsylvania, it brings to question as to whether or not health companies that have the capability to manufacture vaccines, treatments, and test kits against smallpox will be the new growth sector of...
If you haven`t bought at my first call, when PFE was $40: Than you should know that Pfizer’s vaccine with BioNTech SE is on track to be the best-selling drug product on a yearly basis and received backing from a European regulatory panel on Thursday to expand its use into children as young as five. Still low PE Ratio (TTM) 15.42 Decent Forward Dividend &...
^ $BNTX will announce if its possible to revise their current vaccine to accommodate the new strain in 2 weeks and could redesign its vaccine within 6 weeks, with an aim to distribute it within 100 days. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the...
$MRNA $308 or $300 bounce (If we get below then reclaim these levels, take a position for calls) Price targets: 308->310 300->305 Technical analysis: Bounce off pivot point around 308 area or bounce off psychological level at 300 Rationale: With increasing news of a new virus variant, vaccine stocks are rallying so there is built up potential for more momentum
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising...
TMBR Timber Pharmaceuticals had a recent public offering price of $0.64 per share of common stock and accompanying common warrant. The warrants have an exercise price of $0.70 per share. The price is now 0.47usd There is a strong upside potential short term! Price Target 1: $0.85 Price Target 2: $1.37 Stop loss: $0.41 Looking forward to read your opinion about it.
*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* $ATOS remains my teams best trade yet, but sadly for you guys this was...
Hi there. Price is forming a continuation pattern to the upside. Watch strong price action at the current levels for buy.